Page last updated: 2024-11-05

thalidomide and Hydramnios

thalidomide has been researched along with Hydramnios in 1 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tuli, SM1

Reviews

1 review available for thalidomide and Hydramnios

ArticleYear
Certain causes of congenital malformations in Homo sapiens and their prevention.
    Journal of the Indian Medical Association, 1967, Dec-01, Volume: 49, Issue:11

    Topics: Abnormalities, Drug-Induced; Abortion, Therapeutic; Aminopterin; Antigen-Antibody Reactions; Chromos

1967